"Heart failure is a silent killer, so this new way of treating patients is a total gamechanger that I never thought I'd see in my lifetime."
"Strong-HF has allowed us to think completely differently. For the first time ever, we offer patients a review one week after discharge."
In Britain, heart failure patients are now receiving larger initial drug doses following a global study indicating a significant reduction in mortality rates. This treatment, based on the Strong-HF trial, allows patients to receive their optimal medication dosage within two weeks rather than months, lowering death rates by 62% and hospital readmission risks by 30%. Hospitals like St George's and Morriston have adopted this approach, which likens rapid titration to immediate chemotherapy doses in cancer patients, marking a transformative change in heart failure care.
Read at www.theguardian.com
Unable to calculate read time
Collection
[
|
...
]